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The incidence of malignant brain tumors rose steadily over the last quarter of a
century in both adults and children.
1-6 A proportion of this trend may be due to
improved neuro-imaging techniques and access to medical care.
7 Familial gene
mutations, immune disease, and high dose irradiation are known causes of brain
tumors but are likely responsible for a minority of cases. Epidemiological studies
and geographic variability in case numbers suggest that the etiology of brain
tumors may be associated with environmental factors and exposure to carcino-
gens.
7-9 While brain tumors in the United States constitute a minority of cancer
cases, with an incidence of 14.8 brain tumors per 100,000 person years, and
roughly half diagnosed as benign, the malignant forms of brain tumor present a
devastating prospect of morbidity and mortality.
10 The most common malignant
brain tumors are gliomas, and within gliomas, glioblastoma multiforme (GBM)
are the most common, representing 40% of all primary, malignant central nervous
system tumors.
11 GBM have a median overall survival of approximately 1 year.
12
The term “multiforme” in GBM describes the heterogeneous nature of these
neoplasms and their varied histological composition.
13 These tumors are charac-
terized by diffuse infiltration into surrounding tissue that prevents complete
surgical resection. Currently the standard treatment for GBM is surgical resection
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INTRODUCTIONfollowed by a combination of radiotherapy and chemo-
therapy.
14 Due to the poor prognosis of malignant tumors
under this regimen of treatment, discovering effective new
treatment is a crucial goal of further research. In order to
design effective therapy it is imperative that ongoing re-
search aims to understand the molecular pathways essen-
tial in tumor proliferation, survival, and invasion. Another
emerging field of research is to develop an accurate model
of the cell populations and morphogenic processes that
produce the heterogeneous population of cells within a
tumor. In both of these fields, brain tumor stem cells repre-
sent a central concept that remains to be fully determined
and established.
Divergent perspectives on the fundamental nature of brain
tumor biology fuel a debate that revolves around the theory
of brain tumor stem cells (BTSC) as a model of glioma. The
cancer stem cell theory posits that only a specific, minority
of tumor cells possess the ability to produce a tumor and
that these cells may arise from mutations in normal stem or
progenitor cells.
15-17 The brain tumor stem cell theory holds
that BTSC produce all the cells of a tumor and therefore
represent the essential, specific targets of effective treat-
ment necessary to prevent recurrence.
18 The notion that
glioma tumors are caused by transformed neural stem cells
was originally fueled by the discovery that brain tumors
expressed nestin, an intermediate filament that can be
expressed by neural stem cells,
19,20 although it is also ex-
pressed by more limited progenitors as well as by other
cells within the body.
21 In this BTSC model, brain tumor
stem cells arise from oncogenic mutations in neural stem
cells. This hypothesis was supported by several observa-
tions: gliomas can arise near the lateral ventricles, a site
housing neural stem cells that reside in the subventricular
proliferative zone; neural stem cells proliferate enough to
make them susceptible to transformation; and neural stem
cells and BTSC share essential mechanisms for prolifera-
tion and survival.
22,23 
Evidence for the BTSC model of glioma first came from
several laboratories.
24-26 These studies demonstrated biolo-
gical similarities between brain tumor initiating cells and
neural stem cells through the use of neurosphere cultures.
Reynolds and Weiss, et al.
27 originally isolated and enriched
neural stem cells from the adult brain through the use of
neurosphere cultures.
28 Neural stem cells distinguished
themselves from other cells in the brain by their ability to
grow as neurospheres (floating spheres of cells) in relati-
vely simple, serum free media with the addition of epider-
mal growth factor (EGF), basic fibroblast growth factor
(bFGF), or both. Neurospheres could subsequently differ-
entiate into the multiple lineages of brain cells upon remo-
val of growth factors. In like manner, cells derived from
brain tumors form serially passaged clonal neurosphere
cultures in serum free media, and, upon removal of growth
factors, differentiate into multiple lineages to recapitulate
tumor morphologies. In other words, in vitro, BTSC behave
in a similar fashion to neural progenitor cells; they respond
to the same mitogens, and they express similar markers. 
The theory of BTSC was further substantiated when
Galli, et al.
29 demonstrated that GBM derived neurosphere
cultures were tumorigenic upon xenotransplantation into
immunodeficient mice and Singh, et al.
30 demonstrated that
tumor cells expressing CD133 (a putative marker of hu-
man neural stem cells), when sorted from patient samples,
formed tumors in immunodeficient mice while the CD133
negative fraction did not. The theory of BTSC gained accep-
tance and the model developed that BTSC may originate
from transformed neural stem or progenitor cells, and
furthermore, are unique amongst other tumor cells in that
BTSC possess the capacities to extensively self renew,
initiate tumors upon orthotopic transplantation, and give
rise to a heterogeneous population of cells such as those
found in their parent tumors. More recent studies demons-
trated that the ability of glioma tumors to form neuros-
phere cultures is an independent predictor of clinical out-
come.
31,32 These data provide further evidence that BTSC
play a central role in tumor progression and aggressive-
ness. However, BTSC remains a hypothesis and both the
definition and terminology are still debated. Some scientists
prefer the less declarative terms “brain tumor initiating
cells” or “brain tumor stem like cells”. For the purposes of
this paper, we shall use the term brain tumor stem cells.
In order to discover effective treatment for malignant
glioma, one must seek to characterize and target specific
molecular pathways and mechanisms employed by brain
tumor stem cells. While gliomas are classified on the basis
of histopathological criteria into four grades, in ascending
order of malignancy, molecular expression profiling has
also been effective at distinguishing subclasses of glioma.
33
Molecular expression profiles provide an advantage by
offering valuable insights into the specific oncogenic path-
ways that drive tumor proliferation and, thereby, produce a
more specific characterization of each tumor. Classification
of high grade glioma based on molecular expression pro-
files have classified 3-5 distinct types of malignant tumors
that resemble different stages in neurogenesis, predict pa-
Dan Richard Laks, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 5   September 2010 634
BRAIN TUMOR STEM CELLS
MOLECULAR DIAGNOSIS AND 
THERAPYBrain Tumor Stem Cells
Yonsei Med J   http://www.eymj.org    Volume 51   Number 5   September 2010 635
tient prognosis, and indicate that activation of the Akt and
Notch canonical oncogenic pathways reflect the aggressi-
veness of these neoplasms.
34-36 
Many cellular processes involved in regulating neural
stem cells are also essential in glioma brain tumor stem
cells. For example, certain cell cycle regulators and trans-
cription factors involved in the regulation of neural pro-
genitors, such as c-MYC, OCT-4, BMI-1, Olig-2, and
MELK, also regulate brain tumor and putative BTSC
proliferation and survival.
18,37-43 Similarly, multiple secreted
growth factors involved in neural stem cell proliferation,
such as EGF, and IGF (insulin like growth factor), bind with
receptor tyrosine kinases to activate downstream prolifera-
tion and survival pathways in brain tumor initiating cells.
42 
Noteworthy is the PI3 kinase/Akt pathway, a key regul-
ator of signaling via different pathways, including those
regulated by EGF and IGF receptors. The PI3 kinase/Akt
pathway has received a lot of attention as a target for cancer
treatment.
44,45 Recently, expression of Akt and PI3 kinase
activity has been shown to be associated with glioma tumor
grade.
46 There are many agents available to researchers that
specifically target this pathway, and this area of research
promises to change therapeutic strategies utilized in glioma
treatment.
47 Rapamycin is a microbial derived therapeutic
that acts specifically on mTOR.
48-51 mTOR is one downs-
tream effector of the Akt pathway which can also act via a
feedback loop to influence Akt signaling.
52 Recently, ra-
pamycin has made its way to clinical trials for the treatment
of glioma.
53 However, rapamycin treatment in clinical trials
as well as in laboratory trials produces cellular resis-
tance.
53,54 Further research is necessary to determine whe-
ther this resistance is due to the many feedback loops in-
herent in the pathway
55,56 or to some other biological process.
A recent study has suggested that improved inhibitors of
mTOR may decrease resistance.
57,58 
Another critical signaling pathway involved in both neural
progenitor and glioma proliferation and survival is the
Notch pathway.
59-62 Notch is a family of transmembrane
receptors that interact with adjacent cells. Upon ligand
binding to Notch, gamma secretase cleaves the intracellular
portion of the Notch receptor (NICD), thereby releasing
NICD to translocate to the nucleus where it acts as a trans-
cription factor promoting proliferation and inhibiting
differentiation. Evidence is accumulating that the Notch
pathway plays a crucial role in the formation and growth
of glioma tumors
63 and drugs that inhibit gamma secretase
are gaining interest as therapeutic agents in the treatment
of glioma. 
A central concern with utilizing specific drug targets is
whether the redundancy of multiple oncogenic pathways
confers resistance to single-pathway-targeted therapy.
64,65
For example, the Notch pathway and Akt pathway have
been shown to interact in multiple ways
66-70 and this in-
teraction may confer chemoresistance.
66 Hence, many
investigators purport that combinatorial therapy provides a
more robust therapeutic strategy.
71 Besides the Notch and
PI3 kinase pathways, other pathways implicated in glioma
survival are the hedgehog, Wnt, and bone morphogenic
protein pathways. In addition, the post-transcriptional modi-
fication of miRNA’s have also been shown to regulate
glioma.
23,42,72 To address the multiplicity of oncogenic path-
ways, future treatment for glioma patients may include
molecular expression characterization of tumor biopsies
followed by a tailored regimen of combinatorial, targeted
therapy. Efforts in pharmacology research include the
search for synergistic combinations of specific drugs. Ano-
ther aim of research is to determine molecular and genetic
diagnostic criteria for tumor biopsies that are predictive of
which oncogenic pathways are the essential targets for
tailored therapy. 
Chemoresistance represents a known challenge to glio-
ma therapy. In addition to mechanisms of resistance that
are dependent on specific signaling pathways, brain tumors
possess other mechanisms of chemo-resistance. One
example is the ability of O-6-methylguanine-DNA methyl-
transferase (MGMT), a DNA repair protein, to reverse the
DNA damage caused by alkylating agents such as temo-
zolomide that target rapidly dividing cancer cells.
73 In fact,
MGMT-positive expression status in a tumor biopsy pre-
dicts specific resistance to treatment with alkylating agents.
Even more challenging, chemoresistance to a broad spec-
trum of cytotoxic agents, termed multi drug resistance
(MDR), is a characteristic of glioma and represents a
major obstacle in effective treatment.
74 MDR may be the
result of genetic evolution, an adaptation through muta-
tions that occurs during chemotherapy, or it may be an a
priori property of certain tumor cells. In both cases increas-
ed expression of drug transporters, such as the ATP bind-
ing cassette super-family (ABC transporters), act to pump
cytotoxic agents out of the cell.
75 Evidence that a distinct
“side population” exists within tumors with enhanced drug
efflux capacity suggests that MDR may be the intrinsic
property of a minority of distinct tumor cells with enhanced
drug transporting capacity.
76 This multi drug resistant “side
population” is believed to be enriched for brain tumor stem
cells. It is unknown whether MDR is due to an intrinsic
property of BTSC, or to ongoing mutational evolution, or is
the result of a systemic response to treatment.
Many models exist to explain the etiology and function of
the heterogeneous cell populations that form glioma tu-
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mors.
23 The hierarchical model of BTSC contrasts with the
more established stochastic model of cancer in which
variegated cell populations possess equivalent capabilities
to form tumors. In the stochastic model of tumors, different
populations undergo clonal evolution in competition with
each other in a process driven by mutation to form the
tumor bulk.
77 It is thought that multiple mutations are re-
quired to transform a normal cell into a malignant, cancer
cell.
78 Possibly, a mutator phenotype is a requirement to
produce malignant cells.
79 In this model, a primary muta-
tion causes genetic instability that drives further mutations;
this mutator phenotype eventually produces cancerous
cells. In this clonal evolution model of tumors, the diver-
sity of cells within a tumor is not caused by a single BTSC
but by a heterogeneous population of genetically distinct
cancer cells.
Evidence is accruing that tumors are in a state of genetic
flux. Analysis of lymphoblastic leukemia patients revealed
that cancer recurrences differed in DNA copy number from
their original, primary cancers.
80 Similarly, recurrences of
breast cancer tumors were shown to have different muta-
tional profiles than their original, primary tumors.
81 This
evidence suggests that tumors possess a heterogeneous
population of genetically distinct cells that undergo clonal
evolution. The ongoing debate between the cancer stem
cell model and the clonal evolution model has been review-
ed by Shackleton, et al.
82 Glioma seem to fit well within
the cancer stem cell model because tumorigenic capacity is
a relatively rare trait among glioma tumor cells and not a
uniform trait as would be predicted by the clonal evolution
model. Indeed, glioma BTSC have been shown to demon-
strate a hierarchical model,
29 capable of generating a diver-
sity of cells. However, genetic diversity has also been dis-
covered within glioma tumors. A study by Shapiro, et al.
83
in 1981 performed karyotypic analysis of different glioma
tumors and the cultures derived from them and discovered
3-21 genetically distinct subpopulations within the average
glioma tumor with varying chemosensitivities.
84 As this
study was done in an age before neurosphere cultures, one
cannot determine from this experiment how many geneti-
cally distinct, tumorigenic cultures were derived from each
tumor. Recently, Piccirillo, et al.
85 isolated two genetically
distinct populations of cells from distinct regions of a
GBM tumor. However, only one population was tumori-
genic, so one cannot assume that multiple populations of
cancer stem cells existed in that particular tumor. However,
this data does suggest the possibility that genotypically
distinct BTSC may coexist within the same tumor.
It has been demonstrated that there is considerable gene-
tic variability within populations of neural stem cells in the
brain.
86,87 In fact, it can even be assumed that some genetic
variation and instability found in neurosphere cultures
represents the genetic variation and instability within the
brain.
88 A systems based approach may syncretize the
disparate models of glioma in order to address the manifest
complexity of these tumors. In contrast to clonal evolution,
the complex system model we shall discuss considers the
features of adaptive and resistant behavior exhibited by
malignant brain tumors to be the emergent properties of a
complex adaptive system consisting of multiple brain
tumor stem cells. In this model, both genetic and potenti-
ally reversible epigenetic changes may explain not only the
cellular diversity, but also the increased plasticity these
tumors exhibit upon therapeutic intervention.
Cancer has been characterized as a robust, complex sys-
tem
71,89,90 and tumors have been described as a cooperative
system of interacting cells.
91,92 Therefore it is worthwhile to
assess cancer as a complex adaptive system.
93,94 A complex
adaptive system is characterized by emergent, global pro-
perties that are produced by a requisite diversity of local
interactions.
95 These emergent properties are only ascribed
to the complex system itself and cannot be reduced to the
properties of the individual components of the system.
89,94,95
Emergent properties confer the hallmarks of a complex
adaptive system: organization, adaptability, and survival. 
Gliomas fit the essential criteria for a complex adaptive
system, they are heterogeneous, self adaptive and self
organized. Evidence exists for interactions between BTSC
and local environmental cues that play a role in BTSC sur-
vival and proliferation.
96 Autocrine and paracrine factors
are secreted by brain tumor stem cells to enhance infiltra-
tion and migration into surrounding brain tissue.
97 Diffusi-
ble factors and adherence cues emitted from surrounding
vasculature exert an influence on BTSC proliferation and
survival.
98 With all these factors involved in BTSC prolifera-
tion, survival, and infiltration, it is conceivable that a diver-
sity of brain tumor stem cells may arise as a complex adap-
tive system that interacts through diffusible factors and
adherence cues. Recently it has been shown in a drosophila
model that diverse, adjacent tumor cells can cooperate to
produce emergent properties of tumorigenesis and infiltra-
tion.
99 To what extent this occurs in human glioma has yet
to be determined. 
In order to model the tumorigenic process of glioma, it is
necessary to ascertain which processes are involved. Besi-
des the brain tumor stem cell model and the clonal evolu-
tion model are more complex systems whose roles in glio-
ma are in the realm of possibility (Fig. 1). In order to prio-
ritize therapeutic targets of glioma, it is important to have
BRAIN TUMOR STEM CELLS AS 
A COMPLEX ADAPTIVE SYSTEMthe most informative model of glioma tumorigenesis. Fur-
ther research is needed to determine whether de-differen-
tiation occurs, whether BTSC can adapt to treatment by
switching between different phenotypic states that confer
either resistance or growth, whether multiple, genetically
distinct brain tumor stem cells exist within each tumor,
whether a mixture of the clonal model and the BTSC
model co-exist, and to what extent signaling between
BTSC, tumor cells, and the niche provides additional
therapeutic targets. 
To produce a model of glioma with improved diagnostic
and therapeutic prediction-value may require a thorough
understanding of both the essential molecular and mor-
phogenic processes involved in tumor survival and proli-
feration. To devise tailored treatment, predictive molecular
and genetic diagnostic criteria must be ascertained.
Furthermore, it is important to discover whether treatment
resistance in glioma is due to intrinsic characteristics of
cancer stem cells, mutational evolution, redundant mole-
cular pathways, or to the adaptation of a complex system
of multiple brain tumor stem cells. Through the elucidation
of glioma tumor biology, research aims to overcome treat-
ment resistance and devise appropriate therapeutic appro-
aches. BTSC may represent an essential target of therapy.
Targeting the essential pathways and transcription factors
of BTSC may deliver the next generation of improved thera-
peutic options.
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Fig. 1. Different tumor models of GBM. According to the cancer stem cell model (left panel), a subpopulation of cancer cells possesses the capacity of self-renewal,
clonal sphere formation and in vivo tumor formation, as well as the capability to form progeny with a more restricted fate (darker colors). This forms a hierarchical
lineage system where the primary therapeutic cell target is the CSC itself. The clonal evolution model (middle panel) exhibits no lineage hierarchy, as the multiple cell
populations are the result of different genetic mutations (broken arrows). There is no cell hierarchy, because most of these cell subtypes self-renew and are capable of
tumor formation, which makes them all targets of therapeutic interventions. In a complex system (right panel), both genetic and epigenetic changes might occur within
a single tumor, resulting in a multifaceted cell system where several tumor-initiating cell types may coexist. While genetic mutations may produce new tumor cell
populations (#3), epigenetic changes (#2) might enable cells to produce progeny with a more or less restricted fate and also to temporarily adopt different states
characterized by therapy resistance and expression of different cell markers. Another important feature of a complex system is that the individual cell populations
interact (red arrows, #4). While all potential tumor forming cells have to be targeted for successful therapy in this model, the interruption of the cell-cell and cell-niche
interactions may also weaken the tumor system as a whole. GBM, glioblastoma multiforme; CSC, cancer stem cell.
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